Lexicon and Ipsen's MAA for Xermelo given positive opinion by CHMP

The European Commission will now make a final decision on whether to approve the MAA for the drug.
The European Commission will now make a final decision on whether to approve the MAA for the drug. | Contributed image

Lexicon Pharmaceuticals Inc.'s Xermelo, a carcinoid syndrome diarrhea treatment created in collaboration with Ipsen, has been given a positive opinion for Marketing Authorization Application (MAA) by the Committee for Medicinal Products for Human Use (CHMP), the committee of the European Medicines Agency (EMA) responsible for human medicines.

The European Commission will now make a final decision on whether to approve the MAA for the drug, and it will use the CHMP’s recommendation when making its decision. A decision should come by the third quarter of 2017. 

If approved, Xermelo will be authorized for marketing in all 28 countries of the European Union.

"Xermelo was approved in the U.S. in February, and the CHMP’s positive opinion marks another important step forward in providing the first oral treatment option for adults affected by this rare disease in Europe,” Dr. Pablo Lapuerta, Lexicon's executive vice president and chief medical officer, said in a statement. “We thank the carcinoid syndrome community for their continued support, including the adults, families and caregivers who gave their time to participate in the clinical trials of telotristat ethyl with the goal of making this treatment a reality for patients."

Want to get notified whenever we write about Lexicon Pharmaceuticals, Inc. ?
Next time we write about Lexicon Pharmaceuticals, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Lexicon Pharmaceuticals, Inc. 8800 Technology Forest Pl Spring, TX - 77381